{{Drugbox
| Watchedfields = changed
| verifiedrevid = 459430179
| IUPAC_name = (''RS'')-5-(cyclohex-1-en-1-yl)-1,5-dimethyl-1,3-diazinane-2,4,6-trione
| image = Hexobarbital.png
| width = 200px
| chirality = [[Racemic mixture]]
| image2 = Hexobarbital ball-and-stick.png
<!--Clinical data-->
| tradename = Citopan, Evipan, Tobinal
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_CA = Schedule IV
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = Schedule III <!-- OTC / Rx-only -->
| legal_status =
| routes_of_administration =
<!--Pharmacokinetic data-->
| bioavailability =
| protein_bound = 25%
| metabolism =
| elimination_half-life =
| excretion =
<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 56-29-1
| CAS_supplemental = <br/>{{CAS|50-09-9}} (sodium salt)
| ATC_prefix = N01
| ATC_suffix = AF02
| ATC_supplemental =  {{ATC|N05|CA16}}
| PubChem = 3608
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01355
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3482
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = AL8Z8K3P6S
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01071
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5706
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 7728
<!--Chemical data-->
| C=12 | H=16 | N=2 | O=3
| molecular_weight = 236.267 g/mol
| smiles = O=C1N(C(=O)NC(=O)C1(/C2=C/CCCC2)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UYXAWHWODHRRMR-UHFFFAOYSA-N
| melting_point = 146.5
| solubility = 0.435
}}
'''Hexobarbital''' or '''hexobarbitone''', sold both in acid and sodium salt forms as '''Citopan''', '''Evipan''', and '''Tobinal''', is a [[barbiturate]] derivative having [[hypnotic]] and [[sedative]] effects. It was used in the 1940s and 1950s as an agent for inducing [[anesthesia]] for surgery, as well as a rapid-acting, short-lasting hypnotic for general use, and has a relatively fast onset of effects and short duration of action.<ref>Lexikon der Neurowissenschaft: [http://www.spektrum.de/lexikon/neurowissenschaft/hexobarbital/5402 Hexobarbital] {{de icon}}</ref> It was also used to murder women prisoners at Ravensbruck Concentration Camp.<ref>{{Cite book|title=If this is a woman: Inside Ravensbruck: Hitler’s concentration camp for women|last=Helm|first=Sarah|publisher=Abacus|year=2015|isbn=9780349120034|location=London|pages=243-258|quote=|via=}}</ref> Modern barbiturates (such as [[Thiopental]]) has largely supplanted the use of hexobarbital as an anesthetic, as they allow for better control of the depth of anesthesia.<ref>{{Cite web|url=https://pubchem.ncbi.nlm.nih.gov/compound/Hexobarbital#section=Chemical-Vendors|title=Hexobarbital {{!}} C12H16N2O3 - PubChem|last=Pubchem|website=pubchem.ncbi.nlm.nih.gov|access-date=2016-05-02}}</ref> Hexobarbital is still used in some scientific research.<ref>{{cite journal|pmid=26689857|year=2015|author1=Tseilikman|first1=V. E.|title=Duration of hexobarbital-induced sleep and monoamine oxidase activities in rat brain: Focus on the behavioral activity and on the free-radical oxidation|journal=General physiology and biophysics|last2=Kozochkin|first2=D. A.|last3=Manukhina|first3=E. B.|last4=Downey|first4=H. F.|last5=Tseilikman|first5=O. B.|last6=Misharina|first6=M. E.|last7=Nikitina|first7=A. A.|last8=Komelkova|first8=M. V.|last9=Lapshin|first9=M. S.|last10=Kondashevskaya|first10=M. V.|last11=Lazuko|first11=S. S.|last12=Kusina|first12=O. V.|last13=Sahabutdinov|first13=M. V.|doi=10.4149/gpb_2015039|volume=35|issue=2|pages=175–83}}</ref>

==Chemistry==
Hexobarbital is a [[racemic]] white powder with a bitter taste.<ref>{{cite web|url=http://www.vetpharm.uzh.ch/wir/00000005/6291__F.htm|publisher=Vetpharm|title=Hexobarbital|accessdate=18 February 2016}}</ref> It melts at 146.5&nbsp;°C and has a [[dissociation constant]] of 8.2.<ref name="ChemIDplus">{{ChemID|56-29-1}}.</ref>

==References==
{{reflist}}

==Further reading==
* {{Cite journal|last1=Takenoshita |first1=R. |last2=Toki |first2=S. |title=New aspects of hexobarbital metabolism: Stereoselective metabolism, new metabolic pathway via GSH conjugation, and 3-hydroxyhexobarbital dehydrogenases |journal=Yakugaku Zasshi |volume=124 |language=japanese |issue=12 |pages=857–871 |year=2004 |pmid=15577260 |doi=10.1248/yakushi.124.857 |url=http://www.jstage.jst.go.jp/article/yakushi/124/12/857/_pdf |format=pdf }}{{dead link|date=April 2017 |bot=InternetArchiveBot |fix-attempted=yes }}
* {{Cite journal | last1 = Wahlström | first1 = G. | title = A study of the duration of acute tolerance induced with hexobarbital in male rats | journal = Pharmacology, Biochemistry, and Behavior | volume = 59 | issue = 4 | pages = 945–948 | year = 1998 | pmid = 9586853 | doi=10.1016/S0091-3057(97)00543-1}}
* {{Cite journal | last1 = Korkmaz | first1 = S. | last2 = Ljungblad | first2 = E. | last3 = Wahlström | first3 = G. | title = Interaction between flumazenil and the anesthetic effects of hexobarbital in the rat | journal = Brain Research | volume = 676 | issue = 2 | pages = 371–377 | year = 1995 | pmid = 7614008 | doi=10.1016/0006-8993(95)00132-A}}
* {{Cite journal | last1 = Dall | first1 = V. | last2 = Orntoft | first2 = U. | last3 = Schmidt | first3 = A. | last4 = Nordholm | first4 = L. | title = Interaction of the competitive AMPA receptor antagonist NBQX with hexobarbital | journal = Pharmacology, Biochemistry, and Behavior | volume = 46 | issue = 1 | pages = 73–76 | year = 1993 | pmid = 8255925 | doi=10.1016/0091-3057(93)90319-O}}

{{General anesthetics}}
{{Hypnotics and sedatives}}
{{GABAAR PAMs}}

[[Category:Barbiturates]]
[[Category:General anesthetics]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Cyclohexenes]]